Protagonist Therapeutics Inc (PTGX)

01:26 AM

Brokerages Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Price Target at $65.44 - Defense World

01:26 AM

Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025

Apr 25, 2025

Daily Progress: Protagonist Therapeutics Inc (PTGX) Drop -2.84, Closing at 44.85 - DWinneX

Apr 25, 2025

Apr 25, 2025

Bank of Montreal Can Increases Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Apr 25, 2025

Apr 23, 2025

Protagonist Therapeutics Announces Plenary Presentation on VERIF - GuruFocus

Apr 23, 2025

Apr 23, 2025

Protagonist Therapeutics CFO Sells Shares to Cover Tax Obligation - TradingView

Apr 23, 2025

Apr 23, 2025

Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025 | PTGX Stock News - GuruFocus

Apr 23, 2025

Apr 23, 2025

Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025 - standard-journal.com

Apr 23, 2025

Apr 23, 2025

Major Clinical Breakthrough: Rusfertide Phase 3 PV Treatment Data Earns Coveted ASCO Plenary Spot - Stock Titan

Apr 23, 2025

Apr 22, 2025

Cerity Partners LLC Sells 1,185 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Apr 22, 2025

Apr 21, 2025

Legal & General Group Plc Lowers Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Apr 21, 2025

Apr 18, 2025

When the Price of (PTGX) Talks, People Listen - news.stocktradersdaily.com

Apr 18, 2025

Apr 16, 2025

Protagonist Therapeutics Reports Granting of Inducement Award | PTGX Stock News - GuruFocus

Apr 16, 2025

Apr 16, 2025

Protagonist Therapeutics Reports Granting of Inducement Award - guardonline.com

Apr 16, 2025

Apr 16, 2025

Protagonist Awards 20,000 Stock Options to Key New Hire at $46.95 - Stock Titan

Apr 16, 2025

Apr 16, 2025

Alliancebernstein L.P. Trims Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Apr 16, 2025

Apr 15, 2025

The 4.2% return this week takes Protagonist Therapeutics' (NASDAQ:PTGX) shareholders five-year gains to 558% - simplywall.st

Apr 15, 2025

Apr 14, 2025

Geode Capital Management LLC Buys 2,366 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Apr 14, 2025

Apr 11, 2025

Protagonist Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:PTGX - Benzinga

Apr 11, 2025

Apr 11, 2025

Polycythemia Vera Market to Show Remarkable Growth Trends from - openPR.com

Apr 11, 2025

Apr 11, 2025

BTIG maintains Buy on Protagonist Therapeutics stock, $82 target By Investing.com - Investing.com Canada

Apr 11, 2025

Apr 10, 2025

Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study - Benzinga

Apr 10, 2025

Apr 10, 2025

Protagonist Therapeutics (PTGX) Unveils Promising Data for Psori - GuruFocus

Apr 10, 2025

Apr 10, 2025

Revolutionary Once-Daily Pill Achieves Complete Skin Clearance in 75% of Teen Psoriasis Patients - Stock Titan

Apr 10, 2025

Apr 08, 2025

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Sei Investments Co. - Defense World

Apr 08, 2025

Apr 02, 2025

Winners and wishers: 9 potential Bay Area drug approvals coming this yearSan Francisco Business Times - The Business Journals

Apr 02, 2025

Apr 02, 2025

(PTGX) Investment Analysis - news.stocktradersdaily.com

Apr 02, 2025

Mar 25, 2025

Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High? - Yahoo Finance

Mar 25, 2025

Mar 23, 2025

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025 - Bluefield Daily Telegraph

Mar 23, 2025

Mar 22, 2025

Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday - MSN

Mar 22, 2025

Mar 21, 2025

Insider Sell: William Waddill Sells 4,000 Shares of Protagonist Therapeutics Inc (PTGX) - GuruFocus

Mar 21, 2025

Mar 20, 2025

Protagonist Therapeutics Takeda To Lead Regulatory Strategy For Rusfertide In Polycythemia Vera NDA - MarketScreener

Mar 20, 2025

Mar 20, 2025

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. With Losses of $100,000 to Contact the Firm - Business Wire

Mar 20, 2025

Mar 19, 2025

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why - MSN

Mar 19, 2025

Mar 19, 2025

Protagonist Therapeutics director Waddill sells $217,000 in stock By Investing.com - Investing.com South Africa

Mar 19, 2025

Mar 19, 2025

Protagonist Therapeutics director Waddill sells $217,000 in stock - Investing.com

Mar 19, 2025

Mar 18, 2025

Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025? - MSN

Mar 18, 2025

Mar 18, 2025

These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company

Mar 18, 2025

Mar 18, 2025

Fast Company Ranks Protagonist Among Elite Biotech Innovators: 2 FDA Filings Coming - StockTitan

Mar 18, 2025

Mar 16, 2025

D-Wave Quantum And IonQ Are Among Top Mid-Cap Stock Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio? - Benzinga

Mar 16, 2025

Mar 15, 2025

Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey

Mar 15, 2025

Mar 15, 2025

Protagonist Therapeutics CFO Ali Asif sells $1.46 million in stock By Investing.com - Investing.com South Africa

Mar 15, 2025

Mar 15, 2025

Protagonist Therapeutics’ chief medical officer sells $1.7 million in stock By Investing.com - Investing.com Canada

Mar 15, 2025

Mar 14, 2025

Protagonist Therapeutics CFO Ali Asif sells $1.46 million in stock - Investing.com India

Mar 14, 2025

Mar 14, 2025

Protagonist Therapeutics’ chief medical officer sells $1.7 million in stock - Investing.com

Mar 14, 2025